Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Safety and efficacy of an investigational drug in the prevention of thrombocytopenia in recurrent or refractory non-Burkitt's, non-Hodgkin's lymphoma (NHL) or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine and Cisplatin) chemotherapy Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Safety and efficacy of an investigational drug in the prevention of thrombocytopenia in recurrent or refractory non-Burkitt's, non-Hodgkin's lymphoma (NHL) or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine and Cisplatin) chemotherapy conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Safety and efficacy of an investigational drug in the prevention of thrombocytopenia in recurrent or refractory non-Burkitt's, non-Hodgkin's lymphoma (NHL) or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine and Cisplatin) chemotherapy Clinical research trials and Safety and efficacy of an investigational drug in the prevention of thrombocytopenia in recurrent or refractory non-Burkitt's, non-Hodgkin's lymphoma (NHL) or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine and Cisplatin) chemotherapy medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Safety and efficacy of an investigational drug in the prevention of thrombocytopenia in recurrent or refractory non-Burkitt's, non-Hodgkin's lymphoma (NHL) or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine and Cisplatin) chemotherapy. Safety and efficacy of an investigational drug in the prevention of thrombocytopenia in recurrent or refractory non-Burkitt's, non-Hodgkin's lymphoma (NHL) or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine and Cisplatin) chemotherapy Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Safety and efficacy of an investigational drug in the prevention of thrombocytopenia in recurrent or refractory non-Burkitt's, non-Hodgkin's lymphoma (NHL) or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine and Cisplatin) chemotherapy clinical trial. Subjects often receive the most expert healthcare possible for their Safety and efficacy of an investigational drug in the prevention of thrombocytopenia in recurrent or refractory non-Burkitt's, non-Hodgkin's lymphoma (NHL) or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine and Cisplatin) chemotherapy condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.

Home > "S" Clinical Trials Conditions > Safety and efficacy of an investigational drug in the prevention of thrombocytopenia in recurrent or refractory non-Burkitt's, non-Hodgkin's lymphoma (NHL) or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine and Cisplatin) chemotherapy

Safety and efficacy of an investigational drug in the prevention of thrombocytopenia in recurrent or refractory non-Burkitt's, non-Hodgkin's lymphoma (NHL) or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine and Cisplatin) chemotherapy



Safety and efficacy of an investigational drug in the prevention of thrombocytopenia in recurrent or refractory non-Burkitt's, non-Hodgkin's lymphoma (NHL) or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine and Cisplatin) chemotherapy

For Condition: Thrombocytopenia,Non-Hodgkin Lymphoma,Hodgkin Disease
Status: Completed
Sponsor(s): Pfizer ,
Synopsis: Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has been demonstrated to increase platelet counts. This study will test the safety and efficacy of the investigational drug in the prevention of thrombocytopenia in patients with recurrent or refractory intermediate-grade or high-grade non-Burkitt's, non-Hodgkin's lymphoma (NHL), or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine, and Cisplatin) chemotherapy.
Details:
Eligibility:
Study Type:
  Interventional, Prevention
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary. Inclusion Criteria: - Patients must have recurrent or refractory intermediate-grade or high-grade non-Burkitt's, non-Hodgkin's lymphoma (NHL) or Hodgkin's disease and be scheduled for a minimum of 2 cycles of DHAP (Dexamethasone, high-dose Cytarabine and Cisplatin) chemotherapy Exclusion Criteria: - Patients must not have active bleeding (exclusions do apply) or history of platelet disorder
Total Enrollment: 

Location and Contact Information:

Research Center
Omaha,  Nebraska,  68198
United States
 

Research Center
Loma Linda,  California,  92354
United States
 

Research Center
Chicago,  Illinois,  60637
United States
 

Research Center
La Jolla,  California,  92037
United States
 

Research Center
Hershey,  Pennsylvania,  17033
United States
 

Research Center
Tamarac,  Florida,  33321
United States
 

Research Center
Orange,  California,  92868
United States
 

Research Center
Frederick,  Maryland,  21702
United States
 

Research Center
Los Angeles,  California,  90048
United States
 

Research Center
St. Joseph,  Michigan,  49085
United States
 

Research Center
Lake Charles,  Louisiana,  70601
United States
 

Research Center
Coos Bay,  Oregon,  97420
United States
 

Research Center
Detroit,  Michigan,  48202
United States
 

Research Center
Scottsdale,  Arizona,  85260
United States
 

Research Center
Southfield,  Michigan,  48076
United States
 

Research Center
Abingdon,  Virginia,  24211
United States
 

Research Center
Oklahoma City,  Oklahoma,  73104
United States
 

Research Center
Los Angeles,  California,  90033-0804
United States
 

Research Center
Jefferson City,  Missouri,  65109
United States
 

Research Center
Maywood,  Illinois,  60153
United States
 

Research Center
Brooklyn,  New York,  11235
United States
 

Research Center
Pensacola,  Florida,  32514
United States
 

Research Center
Lubbock,  Texas,  79410
United States
 

Research Center
Hollywood,  Florida,  33021
United States
 

Research Center
Durham,  North Carolina,  27705
United States
 


Additional Information:
Study ID Numbers:
  444-ONC-0003-0019; 
Study Start Date: 
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00039910

Other Hodgkin Disease Studies:
1. Safety and efficacy of an investigational drug in the prevention of thrombocytopenia in recurrent or refractory non-Burkitt's, non-Hodgkin's lymphoma (NHL) or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine and Cisplatin) chemotherapy

2. Selective T-Cell Depletion to Reduce Graft-Versus-Host-Disease in Patients Receiving Stem Cell Transplantation to Treat Leukemia, Lymphoma or Myelodysplastic Syndromes

3. Pegfilgrastim PBPC Mobilization Study

4. Gene marked cytotoxic T-cells for patients with relapsed Hodgkin's Lymphoma.

5. A Safety/Efficacy Study of SGN-30 (Antibody) in Patients with Refractory or Recurrent CD30+ Hematologic Malignancies

Related Studies:

Other Hodgkin Disease Clinical Trials
Other California Clinical Trials
Other La Jolla Clinical Trials

Safety and efficacy of an investigational drug in the prevention of thrombocytopenia in recurrent or refractory non-Burkitt's, non-Hodgkin's lymphoma (NHL) or Hodgkin's disease receiving DHAP (Dexamethasone, high-dose Cytarabine and Cisplatin) chemotherapy

Modify your Search

  Other Hodgkin Disease Clinical Trials
  Other California Clinical Trials
  Other La Jolla Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103